In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease

Annals of Neurology

Volumn 40, Issue 3, 1996, Pages 399-410

  Kuhl, D E ^a,b   Minoshima, S ^a   Fessler, J A ^a   Frey, K A ^a   Foster, N L ^a   Ficaro, E P ^a   Wieland, D M ^a   Koeppe, R A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 123; VESAMICOL DERIVATIVE;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN MAPPING; CHOLINERGIC NERVE CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0029808280     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410400309     Document Type: Article

References (68)

1. Kuhl DE, Koeppe RA, Fessier JA, et al. In vivo mapping of cholinergic neurons in the human brain using SPHCT and IBVM. J Nucl Med 1994;35:405-410
2. Perry RH, Candy JM, Perry EK, et al. Extensive loss of choline acetyltransferase activity is not reflected by neuronal loss in the nucleus of Meynert in Alzheimer's disease. Neurosci Lett 1982; 33:311-315
3. Pearson RCA, Sofroniew MV, Cuello AC, et al. Persistence of cholinergic neurons in the basal nucleus in a brain with senile dementia of the Alzheimer's type demonstrated by immunohistochemical staining for choline acetyltransferase. Brain Res 1983;289:375-379
4. Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976;99:459-496
5. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403
6. Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977;1:189
7. Ruberg M, Ploska A, Javoy-Agid F, Agid Y. Muscarinic binding and choline acetyltransferase activity in parkinsonian subjects with reference to dementia. Brain Res 1982;232:129-139
8. Dubois B, Ruberg M, Javoy-Agid F, et al. A subcortico-cortical cholinergic system is affected in Parkinson's disease. Brain Res 1983;288:213-218
9. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219: 1184-1190
10. Candy JM, Perry RH, Perry EK, et al. Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J Neurol Sci 1983;59:277-289
11. Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-126
12. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2:1457-1459
13. Bowen DM, Benton JS, Spillane JA, et al. Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. J Neurol Sci 1982;57:191-202
14. Bierer LM, Haroutunian V, Gabriel S, et al. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of cholinergic deficits. J Neurochem 1995;64:749-760
15. Decker MW. The effects of aging on hippocampal and cortical projections of the forebrain cholinergic system. Brain Res Brain Res Rev 1987;12:423-435
16. 125I-labeled cholinergic nerve marker (-)-5-iodobenzovesamicol. Nucl Med Biol 1993;20:929-937
17. Rogers GA, Parsons SM, Anderson DC, et al. Synthesis, in vitro acetylcholine-storage-blocking activities, and biological properties of derivatives and analogues of trans-2-(4-phenyl-piperidino)cyclohexanol (Vesamicol). J Med Chem 1989;32: 1217-1230
18. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944
19. Rapoport SI. Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: a critical review. Cerebrovasc Brain Metab Rev 1991;3:297-335
20. Hughes CP, Berg L, Danziger WI, et al. A new clinical scale for the staging of dementia. BrJ Psychiatry 1982;140:566-572
21. 18F]fluoro-D-glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. Int J Rad Appl Instrum [B] 1990;17:273-279
22. Minoshima S, Koeppe RA, Mintun MA, et al. Automated detection of the intercommissural (AC-PC) line for stereotactic localization of functional brain images. J Nucl Med 1993;34: 322-329
23. Talairach J, Tournoux P. Co-planar stereoraxic atlas of the human brain. New York: Thieme, 1988
24. Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomical standardization: linear scaling and non-linear warping of functional brain images. J Nucl Med 1994;35:1528-1537
25. 18F]FDG PET. J Nucl Med 1995; 36:1238-1248
26. Kuhl DE, Metter EJ, Benson DF, et al. Similarities of cerebral glucose metabolism in Alzheimer's and parkinsonian dementia. J Cereb Blood Flow Metab 1985;5:S169-S170
27. Pietrzyk U, Herholz K, Heiss WD. Three-dimensional alignment of functional and morphological tomograms. J Comput Assist Tomogr 1990;14:51-59
28. Marien MR, Parsons SM, Altar CA. Quantitative autoradiography of brain binding sites for the vesicular acetylcholine transport blocker 2-(4 phenylpiperidino)cyclohexanol (AH5183). Proc Natl Acad Sci USA 1987;84:876-880
29. 3H]Vesamicol binding in brain: autoradiographic distribution, pharmacology, and effects of cholinergic lesions, Synapse 1988;2:486-493
30. 3H]vesamicol binding in the temporal cortex in patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions. Neuroscience 1990;35:327-333
31. 3H]Vesamicol binding in human brain cholinergic deficiency disorders. Neurosci Lett 1990;117:347-352
32. 3H]vesamicol binding to synaptic vesicle uptake sites for acetylcholine in Alzheimer's disease. Neurology 1991; 41:118 (Abstract)
33. Hicks BW, Rogers GA, Parsons SM. Purification and characterization of a nonvesicular vesamicol-binding protein from electric organ and demonstration of a related protein in mammalian brain. J Neurochem 1991;57:509-519
34. Rogers GA, Kornreich WD, Hand K, Parsons SM. Kinetic and equilibrium characterization of vesamicol receptor ligand complexes with picomolar dissociation constants. Mol Pharmacol 1993;44:633-641
35. Jung Y-W, Van Dort M, Gildersleeve DL, Wieland DM. A radiotracer for mapping cholinergic neurons of the brain. J Med Chem 1990;33:2065-2068
36. Erickson JD, Varoqui H, Schafter MKH, et al. Functional identification of a vesicular acetylcholine transporter and its expression from a "cholinergic" gene locus. J Biol Chem 1994; 269:21929-21932
37. Frackowiak RS, Pozzilli C, Legg NJ, et al. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 1981;104:753-778
38. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217: 408-417
39. Perry EK, Johnson M, Kerwin JM, et al. Convergent cholinergic activities in aging and Alzheimer's disease. Neurobiol Aging 1992;13:393-400
40. Reinikainen KJ, Soininen H, Riekkinen PJ. Neurotransmitter changes in Alzheimer's disease - implications to diagnostics and therapy. J Neurosci Res 1990;27:576-586
41. Araujo DM, Lapchak PA, Robitaille Y, et al. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neurochem 1988;50:1914-1923
42. Perry EK. The cholinergic hypothesis - ten years on. Br Med Bull 1986;42:63-69
43. Hansen LA, DeTeresa R, Davies P, Terry RD. Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer's disease. Neurology 1988; 38:48-54
44. Bird TD, Stranahan S, Sumi SM, Raskind M. Alzheimer's disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups. Ann Neurol 1983;14:284-293
45. Rossor MN, Iversen LL, Reynolds GP, et al. Neurochemical characteristics of early and late onset types of Alzheimer's disease. Br Med J 1984;288:961-964
46. Whitehouse PJ, Price DL, Strubble RG, et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237-1239
47. Kerwin JM, Morris CM, Perry RH, Perry EK. Hippocampal nerve growth factor receptor immunoreactivity in patients with Alzheimer's and Parkinson's disease. Neurosci Lett 1992;143: 101-104
48. Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48: 413-421
49. Sokoloff L. The relationship between function and energy metabolism: its use in the localization of functional activity in the nervous system. Neurosci Res Program Bull 1981;19:159-210
50. Richardson PJ. Quantitation of cholinergic synaptosomes from guinea pig brain. J Neurochem 1981;37:258-260
51. Brun A, Gustafson L. Distribution of cerebral degeneration of Alzheimer's disease. A clinico-pathological study. Arch Psychiat Nervenkr 1976;223:15-33
52. Masliah E, Terry RD, Alford M, et al. Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. Am J Pathol 1991;138:235-246
53. Moutjoy CQ, Roth M, Evans NJR, Evans HM. Cortical neuronal counts in normal elderly controls and demented patients. Neurobiol Aging 1983;4:1-11
54. Beach TG, McGeer EG. Cholinergic fiber loss occurs in the absence of synaptophysin depletion in Alzheimer's disease primary visual cortex. Neurosci Lett 1992;142:253-256
55. Fukuyama H, Harada K, Yamauchi H, et al. Coronal reconstruction images of glucose metabolism in Alzheimer's disease. J Neurol Sci 1991;106:128-134
56. 11C-deoxyglucose accumulation, CSF monoamine metabolites and neuropsychological test performance in patients and healthy subjects. J Neurol Neurosurg Psychiatry 1991;54:672-678
57. Durara R, Grady C, Haxby J, et al. Positron emission tomography in Alzheimer's disease. Neurology 1986;36:879-887
58. DeLeon MJ, George AE, Stylopoulos LA, et al. Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet 1989;2:672-673
59. Jobst KA, Smith AD, Szatmari M, et al. Rapidly progressing atrophy of medial temporal lobe in Alzheimer's disease. Lancet 1994;343:829-830
60. Scheff SW, Sparks DL, Price DA. Quantitative assessment of synoptic density in the entorhinal cortex in Alzheimer's disease. Ann Neurol 1993;34:356-361
61. Dubois B, Pillon B, Thermitte F, Agid Y. Cholinergic deficiency and frontal dysfunction in Parkinson's disease. Ann Neurol 1990;28:117-121
62. 18F]fluorodeoxyglucose method. Ann Neurol 1984;15:419-424
63. Lange KW, Wells FR, Jenner P, Marsden CD. Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease. J Neurochem 1993;60: 197-203
64. Nakano I, Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 1984;5:415-418
65. Perry EK, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia - similarity to Parkinson's and distinction from Alzheimer's disease. Alzheimer Dis Assoc Disord 1993;7:69-79
66. Mazziotta JC, Phelps ME, Plummer D, Kuhl DE. Quantitation in positron emission computed tomography: 5 physical anatomical effects. J Comput Assist Tomogr 1981;5:734-743
67. Folstein M, Folstein SE, McHugh PR. "Mini mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
68. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology (Minneap) 1966;17:427-442